TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
EAST RUTHERFORD, N.J., Oct. 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that third quarter 2017 financial results will be released on Tuesday, November 7, 2017 before the market opens.
The Company will host a conference call to discuss the financial results.
| Third Quarter 2017 Earnings Conference Call | |
| When: | Tuesday, November 7, 2017 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-866-548-4713 for U.S. |
| 1-323-794-2093 for International | |
| Passcode: 1511082 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 1511082 | |
| Available through Tuesday, November 14, 2017 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
Investor Relations Associate
Tel: 201-804-3037
Email: [email protected]
